AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23774275 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA
Number of subjects: 2425
Study 23774275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2425
Study 23321021 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher professional development evaluation
Number of subjects: 562
Study 23321021 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher implementation
Number of subjects: 562
Study 23321021 — intervention group
Group type: EXPERIMENTAL
Intervention: Student reception
Number of subjects: 562
Study 23321021 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher satisfaction with teaching the curriculum
Number of subjects: 562
Study 23321021 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher perception of amount of student work
Number of subjects: 562
Study 20005744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil (average effect site concentration 1.99 +/- 0.02 ng/mL) with epidural analgesia with 0.5% ropivacaine started at the beginning of anesthesia
Number of subjects: 38
Study 20005744 — intervention group
Group type: COMPARATOR
Intervention: High-dose remifentanil (average effect-site concentration 5.61 +/- 0.84 ng/mL) with epidural analgesia started and at the end of surgery
Number of subjects: 38
Study 18155990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacylglycerol oil
Number of subjects: 312
Study 18155990 — intervention group
Group type: COMPARATOR
Intervention: Triacylglycerol oil
Number of subjects: 312
Study 16889593 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy of 10,000 lux/wide spectrum for 3 weeks
Number of subjects: 1
Study 16889593 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (dark sunglasses during sessions)
Number of subjects: 1
Study 12962946 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 126
Study 12962946 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 126
Study 12962946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 11304971 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 50
Study 11304971 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 50
Study 8640980 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion
Number of subjects: 6
Study 1602361 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0
Study 1602361 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine
Number of subjects: 0
Study 1602361 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir suppression
Number of subjects: 0
Study 1602361 — intervention group
Group type: COMPARATOR
Intervention: Foscarnet maintenance therapy
Number of subjects: 0
Study 1602361 — intervention group
Group type: COMPARATOR
Intervention: No chronic antiviral therapy
Number of subjects: 0
Study 6596056 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sodium intake (70-200 mmol/day)
Number of subjects: 0
Study 6596056 — intervention group
Group type: COMPARATOR
Intervention: Reduced sodium intake
Number of subjects: 0
Study 6596056 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sodium intake
Number of subjects: 0
Study 6596056 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium interaction with sodium
Number of subjects: 0
Study 30361322 — intervention group
Group type: EXPERIMENTAL
Intervention: Allen Carr's Easyway to Stop Smoking (AC)
Number of subjects: 300
Study 30361322 — intervention group
Group type: COMPARATOR
Intervention: Quit.ie
Number of subjects: 300
Study 29509579 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 89
Study 29509579 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 89
Study 26038818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT, n = 15)
Number of subjects: 65
Study 26038818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT, n = 32)
Number of subjects: 65
Study 26038818 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n = 18)
Number of subjects: 65
Study 24577230 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at three doses (200 mg, 400 mg, 800 mg/day) for 12 weeks
Number of subjects: 171
Study 24577230 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 171
Study 22118780 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot packs (15min at 60°C)
Number of subjects: 20
Study 22118780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) (15min at 1Mhz)
Number of subjects: 20
Study 20518807 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 0.5 mg
Number of subjects: 623
Study 20518807 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 1 mg
Number of subjects: 623
Study 20518807 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 2 mg
Number of subjects: 623
Study 20518807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 20518807 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant (all doses)
Number of subjects: 623
Study 17952847 — intervention group
Group type: EXPERIMENTAL
Intervention: Common single-nucleotide polymorphisms (SNPs) in seven genes involved in HDL metabolism
Number of subjects: 0
Study 17952847 — intervention group
Group type: COMPARATOR
Intervention: 660 polymorphisms in eight genes not involved in HDL metabolism
Number of subjects: 0
Study 15817602 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC followed by high dose therapy (HDT) consisting of cyclophosphamide, thiotepa, and carboplatin with stem cell rescue
Number of subjects: 281
Study 15817602 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (5-fluorouracil, epirubicin, and cyclophosphamide - FEC for six cycles)
Number of subjects: 281
Study 15817602 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC followed by HDT
Number of subjects: 281
Study 15817602 — intervention group
Group type: COMPARATOR
Intervention: Conventional FEC
Number of subjects: 281
Study 12219032 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin at a rate of at least 1.5 microU/kg/min to maintain serum glucose levels between 100 to 140 mg/dL
Number of subjects: 18
Study 12219032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no insulin treatment)
Number of subjects: 18
Study 10367025 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate at 300 mg load
Number of subjects: 37
Study 10367025 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate at 300 mg load
Number of subjects: 37
Study 10367025 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate at 1000 mg load
Number of subjects: 37
Study 10367025 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate at 1000 mg load
Number of subjects: 37
Study 10367025 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate vs. calcium citrate at high load
Number of subjects: 37
Study 10367025 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate vs. calcium citrate at low load
Number of subjects: 37
Study 10367025 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate vs. calcium citrate at 1000 mg load (urinary increment method)
Number of subjects: 37
Study 7786951 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned cervical smear request form allowing direct notification by mail
Number of subjects: 42
Study 7786951 — intervention group
Group type: COMPARATOR
Intervention: Standard notification process (control group)
Number of subjects: 42
Study 2187013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 180
Study 2187013 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 180
Study 924791 — intervention group
Group type: EXPERIMENTAL
Intervention: Danitracene 1-3 x 0.5 mg/day for 1-3-6 months
Number of subjects: 75
Study 924791 — intervention group
Group type: EXPERIMENTAL
Intervention: Danitracene 1-3 x 0.5 mg/day
Number of subjects: 75
Study 31255452 — intervention group
Group type: EXPERIMENTAL
Intervention: XINSORB bioresorbable sirolimus-eluting scaffold
Number of subjects: 1193
Study 31255452 — intervention group
Group type: COMPARATOR
Intervention: sirolimus-eluting stent (SES)
Number of subjects: 1193
Study 29088439 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoPulse
Number of subjects: 374
Study 29088439 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS
Number of subjects: 374
Study 29088439 — intervention group
Group type: COMPARATOR
Intervention: Manual CC
Number of subjects: 374
Study 25743937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg) with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Number of subjects: 1059
Study 25743937 — intervention group
Group type: COMPARATOR
Intervention: Placebo with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Number of subjects: 1059
Study 25743937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg)
Number of subjects: 1059
Study 25743937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 23902779 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid alone
Number of subjects: 1000
Study 23902779 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B-12 combination
Number of subjects: 1000
Study 23902779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 alone
Number of subjects: 1000
Study 23902779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 21757938 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 48
Study 21757938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 19371315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg b.i.d. for 7 days
Number of subjects: 46
Study 19371315 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine titrated up to 200 mg b.i.d. over 20 days
Number of subjects: 46
Study 17040577 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CIC)
Number of subjects: 0
Study 17040577 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum copper levels
Number of subjects: 0
Study 17040577 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum iron levels
Number of subjects: 0
Study 17040577 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum selenium levels
Number of subjects: 0
Study 17040577 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC, serum copper, iron and selenium
Number of subjects: 0
Study 12571674 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet (high in protein, 27% of energy from protein)
Number of subjects: 20
Study 12571674 — intervention group
Group type: COMPARATOR
Intervention: Control diet (16% of energy from protein)
Number of subjects: 20
Study 12571674 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet
Number of subjects: 20
Study 12571674 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study 11093555 — intervention group
Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament (SWM)
Number of subjects: 10
Study 11093555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration perception thresholds (VPT)
Number of subjects: 10
Study 11093555 — intervention group
Group type: COMPARATOR
Intervention: Screening plus treatment for those with previous ulcers
Number of subjects: 10
Study 9181277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (2 micrograms/kg/min for two hours)
Number of subjects: 21
Study 9181277 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study 1327049 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 micrograms twice daily for 5 days)
Number of subjects: 9
Study 1327049 — intervention group
Group type: COMPARATOR
Intervention: Inhaled PAF (total cumulative dose of 500 micrograms)
Number of subjects: 9
Study 3908329 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (7 mg/kg per day)
Number of subjects: 26
Study 3908329 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg)
Number of subjects: 26
Study 3908329 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 26
Study 3908329 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 26
Study 30514108 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy (n=45)
Number of subjects: 90
Study 30514108 — intervention group
Group type: COMPARATOR
Intervention: Sheet of exercises (n=45; active comparator)
Number of subjects: 90
Study 28920550 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitor (PAM) group, n=38
Number of subjects: 61
Study 28920550 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance required in STS
Number of subjects: 61
Study 28920550 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent in STS
Number of subjects: 61
Study 28920550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mobility improvement
Number of subjects: 61
Study 28920550 — intervention group
Group type: EXPERIMENTAL
Intervention: STS performance
Number of subjects: 61
Study 28920550 — intervention group
Group type: COMPARATOR
Intervention: Group allocation effect on outcomes
Number of subjects: 61
Study 27161860 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone therapy for 12 weeks
Number of subjects: 148
Study 25128076 — intervention group
Group type: EXPERIMENTAL
Intervention: FORTA intervention
Number of subjects: 114
Study 25128076 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 114
Study 22432104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, then 20 μg)
Number of subjects: 361
Study 22432104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 1-step (10 μg for 2 weeks, then 20 μg)
Number of subjects: 361
Study 22432104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (combined 2-step and 1-step)
Number of subjects: 361
Study 22432104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (both regimens)
Number of subjects: 361
Study 22432104 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 361
Study 22432104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 361
Study 22432104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 20562069 — intervention group
Group type: EXPERIMENTAL
Intervention: Elixir DESyne Novolimus Eluting Coronary Stent System (NES)
Number of subjects: 210
Study 20562069 — intervention group
Group type: COMPARATOR
Intervention: Endeavor zotarolimus eluting stent (ZES)
Number of subjects: 210
Study 17621495 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 15
Study 17621495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17621495 — intervention group
Group type: COMPARATOR
Intervention: ADHD children off methylphenidate
Number of subjects: 15
Study 15621328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tester for quantitative measurement of anterior ankle joint laxity
Number of subjects: 24
Study 12232843 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 36
Study 12232843 — intervention group
Group type: COMPARATOR
Intervention: Control (no filgrastim)
Number of subjects: 36
Study 10194055 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 217
Study 10194055 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 217
Study 7552133 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable instruments
Number of subjects: 158
Study 7552133 — intervention group
Group type: COMPARATOR
Intervention: Reusable instruments
Number of subjects: 158
Study 7552133 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 2109927 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion (5 ng/kg/min for 72 hours)
Number of subjects: 27
Study 2109927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study 2109927 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion
Number of subjects: 27
Study 7010886 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25% and 0.5%
Number of subjects: 58
Study 7010886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 1%, 2%, or 4%
Number of subjects: 58
Study 7010886 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg x 3) added if IOP uncontrolled
Number of subjects: 58
Study 7010886 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol once a day administration
Number of subjects: 58
Study 31734151 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage therapy (10-minute sessions, twice during one day, within 30 minutes after opioid pain medication)
Number of subjects: 31
Study 31734151 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (no foot massage)
Number of subjects: 31
Study 30680852 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of varenicline (extended treatment)
Number of subjects: 207
Study 30680852 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of varenicline plus 12 weeks of placebo (standard treatment)
Number of subjects: 207
Study 30680852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 207
Study 28614266 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical information presentation
Number of subjects: 515
Study 28614266 — intervention group
Group type: COMPARATOR
Intervention: Disordered information presentation
Number of subjects: 515
Study 28614266 — intervention group
Group type: COMPARATOR
Intervention: Star rating presentation
Number of subjects: 515
Study 28614266 — intervention group
Group type: COMPARATOR
Intervention: Other aspects of PRCPI
Number of subjects: 515
Study 26360979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (2.67 mmol/L)
Number of subjects: 30
Study 26360979 — intervention group
Group type: COMPARATOR
Intervention: Papaverine (1.0 mmol/L)
Number of subjects: 30
Study 26360979 — intervention group
Group type: COMPARATOR
Intervention: Verapamil-nitroglycerin (30 μmol/L each)
Number of subjects: 30
Study 24151272 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloMatrix bone graft
Number of subjects: 50
Study 24151272 — intervention group
Group type: COMPARATOR
Intervention: No graft
Number of subjects: 50
Study 21377153 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a)
Number of subjects: 96
Study 21377153 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary hCG
Number of subjects: 96
Study 21377153 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle
Number of subjects: 96
Study 19688314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 88
Study 19688314 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 88
Study 19688314 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs (ATH group)
Number of subjects: 88
Study 18823205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuing of specific response subsets grouped by hand or by finger equivalence
Number of subjects: 0
Study 18823205 — intervention group
Group type: COMPARATOR
Intervention: Random baseline condition
Number of subjects: 0
Study 18823205 — intervention group
Group type: EXPERIMENTAL
Intervention: Task switching
Number of subjects: 0
Study 16268244 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist physicians
Number of subjects: 2183
Study 16268244 — intervention group
Group type: EXPERIMENTAL
Intervention: Male physicians
Number of subjects: 2183
Study 16268244 — intervention group
Group type: EXPERIMENTAL
Intervention: Early- and late-career physicians
Number of subjects: 2183
Study 16268244 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 2183
Study 11904526 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 60
Study 11904526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 60
Study 11904526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clopidogrel and ASA
Number of subjects: 60
Study 10559611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bropirimine (3 g/day for 3 consecutive days with a 4-day drug-free interval for up to 1 year)
Number of subjects: 55
Study 10559611 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG (weekly for 2 x 6 weeks)
Number of subjects: 55
Study 10559611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bropirimine
Number of subjects: 55
Study 10559611 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG
Number of subjects: 55
Study 7797904 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI23
Number of subjects: 8
Study 2350615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (1 mg/kg body wt.) by infusion over 4 h
Number of subjects: 25
Study 2350615 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (1 mg/kg body wt.) by infusion over 24 h
Number of subjects: 25
Study 2350615 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined (n = 23)
Number of subjects: 25
Study 7011531 — intervention group
Group type: EXPERIMENTAL
Intervention: POMP (prednisone, vincristine, methotrexate, and 6-mercaptopurine)
Number of subjects: 147
Study 7011531 — intervention group
Group type: COMPARATOR
Intervention: PIP (6-mercaptopurine daily and a prednisone pulse every three months)
Number of subjects: 147
Study 29914146 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinoa-enriched bread (providing 20 g quinoa flour)
Number of subjects: 37
Study 29914146 — intervention group
Group type: COMPARATOR
Intervention: 100% refined wheat bread
Number of subjects: 37
Study 29914146 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinoa-enriched bread
Number of subjects: 37
Study 27893654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine A
Number of subjects: 4000
Study 27893654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine B
Number of subjects: 4000
Study 27893654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine C
Number of subjects: 4000